What is Zacks Research’s Estimate for FOLD Q2 Earnings?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Investment analysts at Zacks Research issued their Q2 2025 earnings per share (EPS) estimates for Amicus Therapeutics in a research note issued on Wednesday, October 16th. Zacks Research analyst R. Department anticipates that the biopharmaceutical company will post earnings of $0.01 per share for the quarter. The consensus estimate for Amicus Therapeutics’ current full-year earnings is ($0.07) per share. Zacks Research also issued estimates for Amicus Therapeutics’ Q4 2025 earnings at $0.10 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.15 EPS and FY2026 earnings at $0.46 EPS.

A number of other analysts have also commented on the company. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, August 9th. Morgan Stanley decreased their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a research note on Friday, September 20th. Finally, Bank of America upped their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.13.

Amicus Therapeutics Stock Up 14.0 %

Amicus Therapeutics stock opened at $11.97 on Thursday. The stock has a market capitalization of $3.55 billion, a PE ratio of -24.43 and a beta of 0.69. Amicus Therapeutics has a twelve month low of $9.02 and a twelve month high of $14.57. The company has a 50 day moving average of $11.16 and a 200-day moving average of $10.56. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The firm had revenue of $126.67 million during the quarter, compared to analysts’ expectations of $121.21 million. During the same quarter in the previous year, the company earned ($0.15) earnings per share. The business’s revenue for the quarter was up 34.0% on a year-over-year basis.

Institutional Investors Weigh In On Amicus Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Amicus Therapeutics by 5.0% during the fourth quarter. Vanguard Group Inc. now owns 28,492,486 shares of the biopharmaceutical company’s stock worth $404,308,000 after purchasing an additional 1,360,613 shares during the period. Assenagon Asset Management S.A. bought a new stake in shares of Amicus Therapeutics during the 2nd quarter worth approximately $8,386,000. M&G Plc boosted its position in shares of Amicus Therapeutics by 12.4% during the 2nd quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after acquiring an additional 82,728 shares in the last quarter. Teachers Retirement System of The State of Kentucky bought a new position in Amicus Therapeutics in the fourth quarter valued at approximately $1,178,000. Finally, Edgestream Partners L.P. raised its position in Amicus Therapeutics by 1,290.4% during the first quarter. Edgestream Partners L.P. now owns 270,164 shares of the biopharmaceutical company’s stock valued at $3,183,000 after purchasing an additional 250,734 shares in the last quarter.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $10,382,718.34. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 22,500 shares of company stock worth $244,875 over the last quarter. Company insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.